Q32 Bio Inc (QTTB) Stock Price, Quote & News - Mboum

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic derm...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 999 0232

Website: www.q32bio.com

Address:

830 Winter Street, Waltham, United States

sbn15 Feb. 2 at 7:43 PM

$QTTB holds very well around 4, when push to 5 ?

0 · Reply

Stef_DL Jan. 29 at 9:25 PM

$QTTB Why look at that 😁

1 · Reply

Stef_DL Jan. 29 at 8:13 PM

$QTTB A solid rebound up. We might even break 4 for once.

0 · Reply

BillionerOfKing Jan. 29 at 11:59 AM

$QTTB Current Stock Price: $3.94

0 · Reply

Bluesclues692 Jan. 27 at 11:45 PM

$QTTB guessing we got another 6 ish weeks to go... sheesh

1 · Reply

anj_rew Jan. 26 at 3:56 PM

$QTTB someone is eager this morning

0 · Reply

JPicks68 Jan. 21 at 10:12 PM

$QTTB get ready for an explosive move up. Low float. Indicators are strong.

0 · Reply

Givemedapesto Jan. 20 at 6:46 PM

$QTTB pick me back up in the 5s

0 · Reply

NotHopeJustFacts Jan. 20 at 5:58 PM

$QTTB 44.3M valuation for some dandrum shampoo company ? no thanks

1 · Reply

amaaaa Jan. 20 at 3:47 PM

$QTTB can you pull a $IBRX 😌

0 · Reply

Latest News on QTTB

Dow Dips 200 Points; Q32 Bio Shares Jump

Dec 1, 2025, 9:58 AM EST - 2 months ago

Dow Dips 200 Points; Q32 Bio Shares Jump

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Dec 1, 2025, 9:43 AM EST - 2 months ago

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 2 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 2 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 3 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 5 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 6 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 10 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 11 months ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 29, 2024, 3:40 AM EDT - 1 year ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

EBS HE HUMA SAVA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 2 years ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

sbn15 Feb. 2 at 7:43 PM

$QTTB holds very well around 4, when push to 5 ?

0 · Reply

Stef_DL Jan. 29 at 9:25 PM

$QTTB Why look at that 😁

1 · Reply

Stef_DL Jan. 29 at 8:13 PM

$QTTB A solid rebound up. We might even break 4 for once.

0 · Reply

BillionerOfKing Jan. 29 at 11:59 AM

$QTTB Current Stock Price: $3.94

0 · Reply

Bluesclues692 Jan. 27 at 11:45 PM

$QTTB guessing we got another 6 ish weeks to go... sheesh

1 · Reply

anj_rew Jan. 26 at 3:56 PM

$QTTB someone is eager this morning

0 · Reply

JPicks68 Jan. 21 at 10:12 PM

$QTTB get ready for an explosive move up. Low float. Indicators are strong.

0 · Reply

Givemedapesto Jan. 20 at 6:46 PM

$QTTB pick me back up in the 5s

0 · Reply

NotHopeJustFacts Jan. 20 at 5:58 PM

$QTTB 44.3M valuation for some dandrum shampoo company ? no thanks

1 · Reply

amaaaa Jan. 20 at 3:47 PM

$QTTB can you pull a $IBRX 😌

0 · Reply

scoon42 Jan. 20 at 3:29 PM

$QTTB $4.25 coming

0 · Reply

Vladdavceo Jan. 20 at 2:53 PM

$QTTB added

0 · Reply

DandyTrades Jan. 15 at 6:30 PM

$QTTB Wont be long now.....

0 · Reply

DandyTrades Jan. 14 at 4:05 PM

$QTTB The ole pipeline means just a matter of time before another strong run in my opinion..... Just need more frequent updates....

0 · Reply

DandyTrades Jan. 12 at 8:29 PM

$QTTB About time for them to drop some more news before to long isnt it......

0 · Reply

amaaaa Jan. 12 at 8:25 PM

$QTTB 👀👀

0 · Reply

DandyTrades Jan. 12 at 4:29 PM

$QTTB Lets get a new HOD.....

0 · Reply

DandyTrades Jan. 9 at 1:05 PM

$QTTB Screw it, lets see a spike to $7 today.... 🚀🚀🚀

0 · Reply

MrEsKurr Jan. 9 at 6:53 AM

$QTTB have a good feeling about this one. Im in at 3.60

1 · Reply

DandyTrades Jan. 8 at 7:47 PM

$QTTB Lets go get another new HOD before close......

0 · Reply

amaaaa Jan. 8 at 4:27 PM

$QTTB what’s the news ?

0 · Reply